A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Phase of Trial: Phase IV
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 29 Nov 2017 Status changed from active, no longer recruiting to completed.
- 30 May 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2017.